RxDoctor Payments Data

Ronald Ebb, MD

Urology · Leominster, MANPI 1851333546

Payments from drug & device makers

$7,088in general payments, 2019–2025

Across 273 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$828
  • Astellas Pharma US Inc$798
  • Sumitomo Pharma America, Inc.$340
  • Urogen Pharma, Inc.$322
  • Teleflex LLC$290
  • Procept Biorobotics Corporation$288
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$6,66894%
  • Education$4206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,088 in reported general payments places this provider in the 75th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$218,385
Medicare patients
677
Services billed
2,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide21$284,050
MyrbetriqMirabegron193$135,693
GemtesaVibegron109$85,391
OrgovyxRelugolix14$37,641
Tamsulosin Hcl1,331$29,884
Solifenacin Succinate120$11,416
Cefpodoxime Proxetil116$9,132
Finasteride582$8,707
XyostedTestosterone Enanthate11$6,811
Trospium Chloride88$5,928
Mirabegron ErMirabegron11$5,805
Oxybutynin Chloride ErOxybutynin Chloride115$5,388
Testosterone Cypionate204$4,794
Alfuzosin Hcl ErAlfuzosin Hcl169$4,483
Tolterodine Tartrate ErTolterodine Tartrate30$2,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$798$419,744214 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$340$123,033123 claims
Antares Pharma, Inc.Xyosted$243$6,81111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 327 urology providers in Massachusetts.

Other urology in Leominster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →